Mixed data for Novo's diabetes drug

Novo Nordisk's long-lasting insulin drug Levemir turned in mixed results in a Phase III trial. Bad news first: Patients taking the drug were less likely to achieve blood sugar control than those taking shorter-acting forms of insulin. But on the flip side, Levemir was less likely to cause weight gain or hypoglycemia. The drug is under investigation for both type 1 and 2 diabetes. The findings were based on results from the first year of a three-year, 5,000 patient study.

"The fact that Levemir provides better glycaemic control, less nocturnal hypoglycaemia and less weight gain relative to NPH insulin over a period of two years is a clinical confirmation of the superior action profile of Levemir," commented Professor Luigi Meneghini, associate director at the Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida. 

- check out this release

ALSO: The FDA has approved Novo Nordisk's Norditropin, a treatment for children with short stature associated with Turner syndrome. Release

Related Articles:
Novo Nordisk reports positive data in diabetes trials. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.